Please login to the form below
24
Revenue 2017Daiichi Sankyo
The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Daiichi Sankyo's 2012 sales performance.
Finalists 2023
for Daiichi Sankyo and AstraZeneca. HER2Know.com: Medical Education to Support HER2 Evolution in Breast Cancer. ... by Havas Lynx Group. for Daiichi Sankyo and AstraZeneca. Unifying Generations.
AstraZeneca/Daiichi Sankyo’s Enhertu approved by EC for advanced breast cancer
AstraZeneca (AZ) and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) has been approved by the European Commission (EC) to treat unresectable or metastatic HER2-low breast cancer. ... Commenting further on the approval, Ken Keller, global head of
AstraZeneca/Daiichi Sankyo’s Enhertu recommended by NICE for advanced breast cancer
AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) has been recommended by the National Institute for Health and Care Excellence (NICE) for the treatment of HER2-positive unresectable or metastatic breast
AstraZeneca/Daiichi Sankyo’s Enhertu approved by EC for advanced gastric cancer
AstraZeneca (AZ) and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) has been approved by the European Commission (EC) as a monotherapy for adult patients with advanced HER2-positive gastric or gastroesophageal junction
AstraZeneca receives CHMP recommendations for Imfinzi, Enhertu and Lynparza
The CHMP also recommended Enhertu (trastuzumab deruxtecan), which is being jointly developed and commercialised with Daiichi Sankyo, as a monotherapy for the treatment of adult patients with advanced HER2-positive gastric
Data provided by GlobalData
GlobalData is the premier source of research and consulting solutions for the pharmaceutical and medical device industries. With the combined expertise of more than 600 researchers, market analysts and consultants, we deliver high-quality, accurate and transparent industry insight that helps our clients to achieve growth and increase business value.
To find out more about how our research and consulting solutions can help you, please visit healthcare.globaldata.com
For more details on the data and methodology used to create the Top Pharma Lists, please visit PMLiVE's Top Pharma List - Methodology
Subscribe to our email news alerts
- Home Based Account Manager, Medical Communications, UK, Pharma/M...
- Highly competitive salary
- Account Director, Healthcare Marketing Creative Agency, Fixed te...
- Highly competitive salary
- Account Manager, Healthcare Marketing Creative Agency, Fixed ter...
- Highly competitive salary
- Market Access Director, six figure base salary and £5K joining b...
- Highly competitive salary
- Senior Medical Copywriter - Highly Awarded Advertising Agency
- £50,000 - £60,000 yearly
- Account Manager, 6 month contract, Healthcare Brand communicatio...
- Highly competitive salary
- Novartis receives EC approval for Cosentyx in hidradenitis suppurativa
- BMS and Janssen’s antithrombotic granted FDA fast track designation
- Sanofi's frexalimab shows promise in relapsing forms of MS
- Amgen reports positive results for Otezla in psoriatic arthritis
- EMA recommends revoking marketing authorisation for Novartis’ sickle cell disease drug
- Seqera Labs and Genomics England partner to progress genomic research
- Pfizer’s antibiotic combination shows promise in treating multi-drug resistant infections
- Supporting the most vulnerable: why pharma should get behind the NHS’ healthcare equity campaign
- Healing the Healers
- The (inevitable) digital transformation of Medical Affairs
- Novartis receives EC approval for Cosentyx in hidradenitis suppurativa
- Pfizer’s RSV vaccine approved by FDA for older adults
No results were found
PMHub
Branding Science
We are Branding Science Partners in thinking which inspires change in healthcare Branding Science are an award-winning global pharmaceutical market...
Latest intelligence
- Healing the Healers
- Because if we do not heal the healers, who is going to heal us?...
- The (inevitable) digital transformation of Medical Affairs
- It’s not a question of ‘if,’ it’s a question of ‘when.’...
- Oncology eBook: Reducing the care gap in cancer prevention, diagnosis, and treatment
- Despite significant innovation in the oncology landscape, there is a growing care gap preventing patients accessing and benefiting from innovations in cancer treatment. In this new publication, our oncology experts...
